PPSG
MACK

Princeton Portfolio Strategies Group’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Princeton Portfolio Strategies Group’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-3,297
Closed -$32K – 183
2017
Q2 		$32K Sell
3,297
-527
-14% -$10.8K 0.01% 164
2017
Q1 		$93K Sell
3,824
-394
-9% -$9.86K 0.03% 172
2016
Q4 		$135K Sell
4,218
-1,959
-32% -$83.5K 0.04% 151
2016
Q3 		$309K Buy
6,177
+475
+8% +$19.7K 0.1% 124
2016
Q2 		$242K Hold
5,702
– – 0.08% 128
2016
Q1 		$375K Buy
5,702
+3,021
+113% +$158K 0.13% 112
2015
Q4 		$167K Buy
2,681
+431
+19% +$30.3K 0.06% 133
2015
Q3 		$151K Buy
2,250
+77
+4% +$6.29K 0.06% 129
2015
Q2 		$211K Sell
2,173
-318
-13% -$30.3K 0.07% 133
2015
Q1 		$233K Sell
2,491
-140
-5% -$11.9K 0.09% 106
2014
Q4 		$234K Buy
+2,631
New +$192K 0.09% 109

Other funds holding MACK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Princeton Portfolio Strategies Group's MACK Position: Q3 2017 in Review

Princeton Portfolio Strategies Group sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q3 2017, closing a stake of 3,297 shares — an estimated $32K sold.

Princeton Portfolio Strategies Group first reported a position in MACK in Q4 2014 and held it in 11 quarters. The position peaked at $375K in Q1 2016. 73 funds tracked by Wall St. Rank hold MACK as of Q3 2017.

  • Princeton Portfolio Strategies Group reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
  • Princeton Portfolio Strategies Group sold 3,297 Merrimack Pharmaceuticals, Inc. shares in Q3 2017, an estimated $32K.
  • Princeton Portfolio Strategies Group first reported a position in Merrimack Pharmaceuticals, Inc. in Q4 2014 and held it in 11 quarters.
  • Princeton Portfolio Strategies Group's Merrimack Pharmaceuticals, Inc. position peaked at $375K in Q1 2016.
  • 73 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q3 2017.

Based on Princeton Portfolio Strategies Group's 13F filing for Q3 2017, filed 14 Nov 2017.